13
Apr
2010
Posted in I - Series C, Q - 1Q10, R - INTERNATIONAL, X - Biologics Mfg., X - PEG
PolyTherics (United Kingdom) a clinical-stage protein engineering company focused on site-specific PEGylation of biologics, closed a $4M Series C financing. Participants include Imperial Innovations, Longbow Capital and The Capital Fund.